Liver function effects of <scp>SGLT2</scp> inhibitor and <scp>GLP</scp>‐1 receptor agonist combination treatment in patients with type 2 diabetes (post hoc analysis of <scp>RECAP</scp> study)
SGLT2i + GLP1Ra combination treatment significantly improved liver dysfunction and prevented the progression of FIB-4 index category among patients with an FIB-4 index ≥1.3.
Authors
- Shunichiro Tsukamoto (ORCID: https://orcid.org/0000-0003-1146-6810)
- Kei Takeshita (ORCID: https://orcid.org/0000-0001-7610-498X)
- Takuya Hashimoto (ORCID: https://orcid.org/0000-0002-7690-1046)
- Yoshimi Muta
- Kazuo Kobayashi (ORCID: https://orcid.org/0000-0002-1284-9728)
- Daisuke Tsuriya (ORCID: https://orcid.org/0009-0001-7891-5046)
- Masao Toyoda (ORCID: https://orcid.org/0000-0003-4142-1218)
- Moritsugu Kimura (ORCID: https://orcid.org/0000-0001-8789-6425)
- Keizo Kanasaki (ORCID: https://orcid.org/0000-0002-9563-502X)
- Kouichi Tamura (ORCID: https://orcid.org/0000-0002-0660-5372)
- Yuichi Takashi (ORCID: https://orcid.org/0000-0002-3728-1139)
- Hisashi Yokomizo (ORCID: https://orcid.org/0000-0001-7759-2014)
- Daiji Kawanami (ORCID: https://orcid.org/0000-0002-8926-4701)
Institutions
- Tokai University (JP)
- Shimane University (JP)
- Hamamatsu University School of Medicine (JP)
- Fukuoka University (JP)
- Yokohama City University (JP)
Publication Details
- Journal
- Journal of Diabetes Investigation
- Published
- 2025-05-07
- DOI
- https://doi.org/10.1111/jdi.70066
- Citations
- 4
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 5.18
Funders
- Eli Lilly and Company
- AstraZeneca
- Sanofi
- Kowa Company
- Boehringer Ingelheim Japan
- Fuji Pharma
- Nipro
- Novo Nordisk
- Astellas Pharma
- Otsuka Pharmaceutical
- Mitsubishi Tanabe Pharma Corporation
- Ono Pharmaceutical
- Bayer Yakuhin
- Novo Nordisk Pharma